FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118932957> ?p ?o ?g. }

• W2118932957 endingPage "2112" @default.
• W2118932957 startingPage "2106" @default.
• W2118932957 abstract "OBJECTIVE—The objective of this study was to evaluate the safety and short-term effect of adding spironolactone to conventional antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor or an angiotensin II receptor blocker (ARB) on albuminuria and blood pressure in type 2 diabetic patients with nephropathy. RESEARCH DESIGN AND METHODS—Twenty-one type 2 diabetic patients with nephropathy were enrolled in a randomized, double-masked, cross-over study. Patients were treated in random order with spironolactone 25 mg once daily and matched placebo for 8 weeks, respectively, in addition to ongoing antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor and/or an ARB. At the end of each treatment period, albuminuria, 24-h ambulatory blood pressure (ABP), and glomerular filtration rate (GFR) were determined. RESULTS—During the addition of placebo, values were as follows: albuminuria (geometric mean [range]) 1,566 [655–7,762] mg/24 h, ABP (mean ± SE) 138 ± 3/71 ± 1 mmHg, and GFR (mean ± SE) 74 ± 6 ml/min per 1.73 m2. During the addition of spironolactone, albuminuria was reduced by 33% (95% CI 25–41) (P &lt; 0.001), fractional clearance of albumin by 40% (24–53) (P &lt; 0.001), and 24-h ABP by 6 mmHg (2–10) for systolic and 4 mmHg (2–6) for diastolic (P &lt; 0.001 for both). The change in albuminuria did not correlate with the change in systolic 24-h ABP (r = 0.19, P = 0.42) or diastolic 24-h ABP (r = 0.01, P = 0.96). Spironolactone treatment induced an insignificant reversible reduction in GFR of 3 ml/min per 1.73 m2 (−0.3 to 6) (P = 0.08). One patient was excluded from the study due to hyperkalemia. Otherwise treatment was well tolerated. CONCLUSIONS—Our study suggests that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy." @default.
• W2118932957 created "2016-06-24" @default.
• W2118932957 creator A5044496367 @default.
• W2118932957 creator A5063227767 @default.
• W2118932957 creator A5072740074 @default.
• W2118932957 creator A5077987218 @default.
• W2118932957 creator A5086470742 @default.
• W2118932957 date "2005-09-01" @default.
• W2118932957 modified "2023-10-16" @default.
• W2118932957 title "Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy" @default.
• W2118932957 cites W1963232607 @default.
• W2118932957 cites W1964527653 @default.
• W2118932957 cites W1992719998 @default.
• W2118932957 cites W2003508199 @default.
• W2118932957 cites W2007854458 @default.
• W2118932957 cites W2017268330 @default.
• W2118932957 cites W2019270553 @default.
• W2118932957 cites W2027790713 @default.
• W2118932957 cites W2044773944 @default.
• W2118932957 cites W2049022568 @default.
• W2118932957 cites W2056976690 @default.
• W2118932957 cites W2059346848 @default.
• W2118932957 cites W2066344356 @default.
• W2118932957 cites W2069802171 @default.
• W2118932957 cites W2072543770 @default.
• W2118932957 cites W2084343172 @default.
• W2118932957 cites W2090526184 @default.
• W2118932957 cites W2096645292 @default.
• W2118932957 cites W2096875294 @default.
• W2118932957 cites W2104158979 @default.
• W2118932957 cites W2109996890 @default.
• W2118932957 cites W2115932546 @default.
• W2118932957 cites W2120150202 @default.
• W2118932957 cites W2126820850 @default.
• W2118932957 cites W2139968474 @default.
• W2118932957 cites W2140172772 @default.
• W2118932957 cites W2148155169 @default.
• W2118932957 cites W2152094259 @default.
• W2118932957 cites W2160541810 @default.
• W2118932957 cites W2163709605 @default.
• W2118932957 cites W2166377713 @default.
• W2118932957 cites W2323458614 @default.
• W2118932957 cites W2615684303 @default.
• W2118932957 cites W2769696378 @default.
• W2118932957 cites W3021250193 @default.
• W2118932957 cites W3198570063 @default.
• W2118932957 cites W4206439534 @default.
• W2118932957 doi "https://doi.org/10.2337/diacare.28.9.2106" @default.
• W2118932957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16123474" @default.
• W2118932957 hasPublicationYear "2005" @default.
• W2118932957 type Work @default.
• W2118932957 sameAs 2118932957 @default.
• W2118932957 citedByCount "276" @default.
• W2118932957 countsByYear W21189329572012 @default.
• W2118932957 countsByYear W21189329572013 @default.
• W2118932957 countsByYear W21189329572014 @default.
• W2118932957 countsByYear W21189329572015 @default.
• W2118932957 countsByYear W21189329572016 @default.
• W2118932957 countsByYear W21189329572017 @default.
• W2118932957 countsByYear W21189329572018 @default.
• W2118932957 countsByYear W21189329572019 @default.
• W2118932957 countsByYear W21189329572020 @default.
• W2118932957 countsByYear W21189329572021 @default.
• W2118932957 countsByYear W21189329572022 @default.
• W2118932957 countsByYear W21189329572023 @default.
• W2118932957 crossrefType "journal-article" @default.
• W2118932957 hasAuthorship W2118932957A5044496367 @default.
• W2118932957 hasAuthorship W2118932957A5063227767 @default.
• W2118932957 hasAuthorship W2118932957A5072740074 @default.
• W2118932957 hasAuthorship W2118932957A5077987218 @default.
• W2118932957 hasAuthorship W2118932957A5086470742 @default.
• W2118932957 hasBestOaLocation W21189329571 @default.
• W2118932957 hasConcept C126322002 @default.
• W2118932957 hasConcept C126894567 @default.
• W2118932957 hasConcept C134018914 @default.
• W2118932957 hasConcept C142724271 @default.
• W2118932957 hasConcept C149323552 @default.
• W2118932957 hasConcept C159641895 @default.
• W2118932957 hasConcept C204787440 @default.
• W2118932957 hasConcept C27016395 @default.
• W2118932957 hasConcept C27081682 @default.
• W2118932957 hasConcept C2776174234 @default.
• W2118932957 hasConcept C2776379505 @default.
• W2118932957 hasConcept C2778198053 @default.
• W2118932957 hasConcept C2779611605 @default.
• W2118932957 hasConcept C2779922275 @default.
• W2118932957 hasConcept C2781184683 @default.
• W2118932957 hasConcept C2781203188 @default.
• W2118932957 hasConcept C555293320 @default.
• W2118932957 hasConcept C71924100 @default.
• W2118932957 hasConcept C84393581 @default.
• W2118932957 hasConceptScore W2118932957C126322002 @default.
• W2118932957 hasConceptScore W2118932957C126894567 @default.
• W2118932957 hasConceptScore W2118932957C134018914 @default.
• W2118932957 hasConceptScore W2118932957C142724271 @default.
• W2118932957 hasConceptScore W2118932957C149323552 @default.
• W2118932957 hasConceptScore W2118932957C159641895 @default.
• W2118932957 hasConceptScore W2118932957C204787440 @default.

• next